ApoE4 Vesicle pH Modulation for Synaptic Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
ApoE4 genotype impairs synaptic plasticity and neuronal function by sequestering ApoE receptors in intracellular compartments, leading to accelerated onset of dementia and neuronal degeneration, as it reduces the ability of Reelin to enhance NMDA receptor activity and maintain synaptic stability.
Innovation Solution
Administering pharmaceutically acceptable modulators of intracellular ApoE4 transport vesicle pH, such as NHE inhibitors, weak bases like aminoquinolines, or proton pump inhibitors, to restore normal ApoE receptor function and trafficking, thereby reversing synaptic dysfunction and preventing premature neuronal loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ApoE4 isoform is present in the brain, then synaptic plasticity and NMDA receptor activation are impaired, but this leads to intracellular retention of ApoE receptors and reduced neuronal surface expression
Solution Approach 1:
The patent changes the pH parameter of intracellular vesicles by administering pH-modulating agents (weak bases like aminoquinolines or proton pump inhibitors). This pH change alters the trafficking behavior of ApoE4-receptor complexes, preventing their permanent intracellular retention and promoting their return to the neuronal surface, thereby resolving the harmful sequestration effect while maintaining synaptic stability.
2Productivity
If Reelin signaling is enhanced to improve synaptic plasticity, then NMDA receptor activity should increase, but ApoE4 sequestration of receptors blocks this pathway
Solution Approach 1:
By modulating intracellular vesicle pH, the patent changes the trafficking dynamics of ApoE4-receptor complexes. This parameter change prevents the sequestration that blocks Reelin signaling, allowing Reelin to effectively enhance NMDA receptor activity and maintain synaptic plasticity despite the presence of ApoE4 isoform.
3Reliability
If pH modulators are administered to restore ApoE receptor trafficking, then neuronal surface expression of receptors increases, but chronic administration is required for sustained effect
Solution Approach 1:
The patent requires chronic administration of pH modulators to maintain the altered trafficking dynamics of ApoE4-receptor complexes. Continuous treatment ensures sustained normalization of receptor surface expression and function, preventing the return to pathological sequestration patterns that would occur if treatment were discontinued.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment effectively normalizes ApoE receptor recycling, alleviates synaptic and neuronal network dysfunction, and prevents premature neuronal loss in ApoE4 carriers by enhancing ApoE4 cycling and trafficking, effectively converting the ApoE4 phenotype to the ApoE3 phenotype.
Implementation Method 1
contacting the person with an effective amount of a pharmaceutically-acceptable modulator of intracellular ApoE4 transport vesicle pH
Implementation Method 2
the modulator is a sodium-hydrogen exchanger (NHE) inhibitor
Data Source
AI summary
Cycling of ApoE4 isoform is promoted in a person in need thereof by contacting the person with an effective amount of a pharmaceutically-acceptable modulator of intracellular ApoE4 transport vesicle pH.